|
||||||||||||||||||||||||||
| SEC Info℠ | | | Home | | | Search | | | My Interests | | | Help | | | Sign In | | | Please Sign In | |||||||
|
||||||||||||||||||||||||||
As Of Filer Filing For·On·As Docs:Size Issuer Filing Agent 3/14/18 Biolase, Inc 10-K 12/31/17 82:13M ActiveDisclosure/FA |
Document/Exhibit Description Pages Size
1: 10-K Annual Report HTML 1.19M
2: EX-4.4 Instrument Defining the Rights of Security Holders HTML 64K
3: EX-10.26 Material Contract HTML 172K
4: EX-10.27 Material Contract HTML 155K
5: EX-10.28 Material Contract HTML 149K
6: EX-10.29 Material Contract HTML 142K
7: EX-21.1 Subsidiaries List HTML 21K
8: EX-23.1 Consent of Experts or Counsel HTML 25K
9: EX-31.1 Certification -- §302 - SOA'02 HTML 31K
10: EX-31.2 Certification -- §302 - SOA'02 HTML 31K
11: EX-32.1 Certification -- §906 - SOA'02 HTML 25K
12: EX-32.2 Certification -- §906 - SOA'02 HTML 25K
19: R1 Document and Entity Information HTML 53K
20: R2 Consolidated Balance Sheets HTML 110K
21: R3 Consolidated Balance Sheets (Parenthetical) HTML 44K
22: R4 Consolidated Statements Of Operations And HTML 98K
Comprehensive Loss
23: R5 Consolidated Statements Of Shareholders' Equity HTML 85K
24: R6 Consolidated Statements Of Shareholders' Equity HTML 25K
(Parenthetical)
25: R7 Consolidated Statements Of Cash Flows HTML 119K
26: R8 Basis of Presentation HTML 49K
27: R9 Summary of Significant Accounting Policies HTML 166K
28: R10 Supplementary Balance Sheet Information HTML 183K
29: R11 Intangible Assets and Goodwill HTML 74K
30: R12 Income Taxes HTML 218K
31: R13 Commitments and Contingencies HTML 48K
32: R14 Stockholders' Equity HTML 397K
33: R15 Segment Information HTML 69K
34: R16 Concentrations HTML 89K
35: R17 Subsequent Events (Unaudited) HTML 32K
36: R18 Schedule II-Consolidated Valuation and Qualifying HTML 117K
Accounts and Reserves
37: R19 Summary of Significant Accounting Policies HTML 264K
(Policies)
38: R20 Summary of Significant Accounting Policies HTML 126K
(Tables)
39: R21 Supplementary Balance Sheet Information (Tables) HTML 192K
40: R22 Intangible Assets and Goodwill (Tables) HTML 68K
41: R23 Income Taxes (Tables) HTML 217K
42: R24 Commitments and Contingencies (Tables) HTML 37K
43: R25 Stockholders' Equity (Tables) HTML 353K
44: R26 Segment Information (Tables) HTML 70K
45: R27 Concentrations (Tables) HTML 89K
46: R28 Basis of Presentation - Additional Information HTML 113K
(Detail)
47: R29 Summary of Significant Accounting Policies - HTML 74K
Additional Information (Detail)
48: R30 Estimated Useful Lives of Property, Plant and HTML 37K
Equipment (Detail)
49: R31 Changes in Initial Product Warranty Accrual and HTML 38K
Expenses Under Initial and Extended Warranties
(Detail)
50: R32 Classification of Compensation Expense Associated HTML 37K
with Share-Based Payments (Detail)
51: R33 Assumptions Used in Estimating Fair Value of Stock HTML 33K
Options Granted (Detail)
52: R34 Components of Accounts Receivable, Net of HTML 32K
Allowance (Detail)
53: R35 Supplementary Balance Sheet Information - HTML 41K
Additional Information (Detail)
54: R36 Components of Inventory (Detail) HTML 33K
55: R37 Summary of Property, Plant, and Equipment (Detail) HTML 50K
56: R38 Components of Accrued Liabilities (Detail) HTML 46K
57: R39 Summary of Deferred Revenue (Detail) HTML 45K
58: R40 Intangible Assets and Goodwill - Additional HTML 32K
Information (Detail)
59: R41 Intangible Assets and Related Accumulated HTML 50K
Amortization (Detail)
60: R42 Summary of Income Tax Current and Deferred HTML 43K
Provision (Detail)
61: R43 Federal Income Tax Provision Compared With HTML 51K
Statutory Rates (Detail)
62: R44 Summary of Net Deferred Tax Assets and Net HTML 72K
Deferred Tax Liabilities (Detail)
63: R45 Income Taxes - Additional Information (Detail) HTML 73K
64: R46 Summary of Unrecognized Tax Benefits (Detail) HTML 30K
65: R47 Commitments and Contingencies - Additional HTML 60K
Information (Detail)
66: R48 Future Minimum Rental Commitments Under Lease HTML 36K
Agreements (Detail)
67: R49 Stockholders' Equity - Additional Information HTML 810K
(Detail)
68: R50 Summary of Warrant Activity (Detail) HTML 57K
69: R51 Summary of Option Activity (Detail) HTML 70K
70: R52 Options Outstanding and Exercisable (Detail) HTML 65K
71: R53 Cash Proceeds Along with Fair Value Disclosures HTML 35K
Related to Grants, Exercises, and Vesting Options
(Detail)
72: R54 Summary of Unvested Restricted Stock Units HTML 36K
(Detail)
73: R55 Segment Information - Additional Information HTML 37K
(Detail)
74: R56 Summary of Net Revenue by Geographic Location HTML 30K
(Detail)
75: R57 Summary of Long-Lived Assets by Geographic HTML 32K
Location (Detail)
76: R58 Concentrations - Summary of Net Revenue from HTML 49K
Various Products (Detail)
77: R59 Concentrations - Additional Information (Detail) HTML 31K
78: R60 Subsequent Events (unaudited) - Additional HTML 101K
Information (Detail)
79: R61 Consolidated Valuation and Qualifying Accounts and HTML 38K
Reserves (Detail)
81: XML IDEA XML File -- Filing Summary XML 136K
80: EXCEL IDEA Workbook of Financial Reports XLSX 103K
13: EX-101.INS XBRL Instance -- biol-20171231 XML 3.68M
15: EX-101.CAL XBRL Calculations -- biol-20171231_cal XML 203K
16: EX-101.DEF XBRL Definitions -- biol-20171231_def XML 699K
17: EX-101.LAB XBRL Labels -- biol-20171231_lab XML 1.56M
18: EX-101.PRE XBRL Presentations -- biol-20171231_pre XML 1.15M
14: EX-101.SCH XBRL Schema -- biol-20171231 XSD 227K
82: ZIP XBRL Zipped Folder -- 0001564590-18-005648-xbrl Zip 223K
 | Download this zipped .zip folder |
| Files: | biol-20171231.xml biol-20171231.xsd biol-20171231_cal.xml biol-20171231_def.xml biol-20171231_lab.xml biol-20171231_pre.xml |
As Of Filer Filing For·On·As Docs:Size Issuer Filing Agent 11/10/21 Biolase, Inc. 10-Q 9/30/21 84:13M Donnelley … Solutions/FA 8/13/21 Biolase, Inc. 10-Q 6/30/21 80:12M Donnelley … Solutions/FA 5/13/21 Biolase, Inc. 10-Q 3/31/21 81:9.4M Donnelley … Solutions/FA 3/31/21 Biolase, Inc. 10-K 12/31/20 88:15M ActiveDisclosure/FA 12/08/20 Biolase, Inc. S-1/A 3:585K Donnelley … Solutions/FA 11/13/20 Biolase, Inc. 10-Q 9/30/20 81:11M ActiveDisclosure/FA 8/14/20 Biolase, Inc. 10-Q 6/30/20 89:12M ActiveDisclosure/FA |